Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Crucell
|
| gptkbp:age |
12 months
|
| gptkbp:approves |
gptkb:United_States
|
| gptkbp:average_temperature |
2 to 8 degrees Celsius
|
| gptkbp:campaigns |
conducted to increase coverage
|
| gptkbp:clinical_trial |
conducted before approval
|
| gptkbp:contraindication |
pregnancy
severe allergic reaction to vaccine components |
| gptkbp:covered_by |
part of routine immunization programs
95% to achieve herd immunity |
| gptkbp:defense |
included in childhood vaccination programs
|
| gptkbp:developed_by |
gptkb:Merck_&_Co.
|
| gptkbp:dosage_form |
recommended at 4-6 years
|
| gptkbp:healthcare |
supported by health organizations
reduces incidence of congenital rubella syndrome |
| https://www.w3.org/2000/01/rdf-schema#label |
Rubella vaccine
|
| gptkbp:introduced |
gptkb:1969
|
| gptkbp:is_documented_in |
required for school entry in some areas
|
| gptkbp:is_effective_against |
approximately 97% after two doses
|
| gptkbp:is_vulnerable_to |
available in many countries
part of global vaccination efforts two doses recommended addressing vaccine hesitancy requires trained healthcare provider may vary by region monitored through epidemiological studies contributes to global health initiatives managed by health authorities ongoing for improved formulations monitored post-licensure available from health departments based on rubella virus strain campaigns to inform about benefits collaborations with NG Os and governments critical for outbreak response essential for safety assessments focus on improving delivery methods high in immunocompetent individuals important for parents and guardians includes studies on long-term immunity live attenuated rubella virus significantly reduced rubella cases updated based on epidemiological data varies by country and provider |
| gptkbp:legislation |
may be mandated in certain jurisdictions
|
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:moral |
considerations in vaccine distribution
|
| gptkbp:part_of |
gptkb:MMR_vaccine
|
| gptkbp:public_awareness |
important for public health education
|
| gptkbp:side_effect |
rash
joint pain mild fever rarely causes serious side effects |
| gptkbp:targets |
gptkb:rubella
|
| gptkbp:type |
live attenuated vaccine
|